New hope for pancreatic cancer: experimental drug DZ-002 enters phase 2 trial

This study tests a new drug called DZ-002 in adults with metastatic pancreatic cancer that has not spread through families. Participants have already completed at least 4 months of standard chemotherapy and their disease is stable. The drug is given weekly through an IV in 4-week cycles. The main goals are to find the best dose and check if it is safe and helps control the cancer. Possible side effects include nausea, fatigue, low blood counts, and skin rash.